Table 1.
Baseline characteristics of patients with/without fPAC
| Patients (n) | fPAC (+) (n:189) | fPAC (−) (n:203) | p |
|---|---|---|---|
| Age, years | 58.83 ± 14.37 | 56.34 ± 15.60 | .102 |
| Sex (male, n [%]) | 91 (48%) | 81 (39%) | .100 |
| HT n (%) | 90 (47%) | 74 (36%) | .025 |
| DM n (%) | 58 (30%) | 44 (21%) | .042 |
| CVA/TIA n (%) | 7 (3%) | 5 (2%) | .476 |
| CAD n (%) | 39 (20%) | 24 (11%) | .018 |
| CHF n (%) | 32 (17%) | 19 (9%) | .026 |
| LVH n (%) | 91 (48%) | 54 (26%) | <.001 |
| LVEF (%) | 54.43 ± 8.23 | 55.28 ± 9.38 | .347 |
| PASP mm Hg | 33.67 ± 11.20 | 32.41 ± 7.58 | .193 |
| LAD mm | 39.83 ± 5.85 | 36.06 ± 7.46 | <.001 |
| CHA2DS2‐VASC score | 2.42 ± 1.06 | 1.42 ± 0.65 | <.001 |
| PAC number | 2,543 (1311–6439) | 101 (0–187) | <.001 |
| Treatment | |||
| ACEi/ARB | 69 (36%) | 59 (29%) | .116 |
| Beta‐blocker | 74 (39%) | 55 (27%) | .011 |
| Statins | 43 (22%) | 36 (17%) | .216 |
Bold values indicates p < .05 are statistically significant.
Abbreviations: ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; CHF, congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; DM, diabetes mellitus; HT, hypertension; LAD, left atrium diameter; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; PAC, premature atrial contraction; PASP, pulmonary artery systolic pressure.